- Home
- DHY vs ZVRA Comparison
DHY vs ZVRA Comparison
Compare DHY & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- ZVRA
- Stock Information
- Founded
- DHY 1998
- ZVRA 2006
- Country
- DHY United States
- ZVRA United States
- Employees
- DHY N/A
- ZVRA N/A
- Industry
- DHY Finance/Investors Services
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- ZVRA Health Care
- Exchange
- DHY Nasdaq
- ZVRA Nasdaq
- Market Cap
- DHY 216.5M
- ZVRA 499.9M
- IPO Year
- DHY N/A
- ZVRA 2015
- Fundamental
- Price
- DHY $2.02
- ZVRA $9.14
- Analyst Decision
- DHY
- ZVRA Strong Buy
- Analyst Count
- DHY 0
- ZVRA 7
- Target Price
- DHY N/A
- ZVRA $21.71
- AVG Volume (30 Days)
- DHY 569.1K
- ZVRA 1.5M
- Earning Date
- DHY 01-01-0001
- ZVRA 11-05-2025
- Dividend Yield
- DHY 9.10%
- ZVRA N/A
- EPS Growth
- DHY N/A
- ZVRA N/A
- EPS
- DHY N/A
- ZVRA 0.54
- Revenue
- DHY N/A
- ZVRA $84,388,000.00
- Revenue This Year
- DHY N/A
- ZVRA $336.43
- Revenue Next Year
- DHY N/A
- ZVRA $54.26
- P/E Ratio
- DHY N/A
- ZVRA $16.99
- Revenue Growth
- DHY N/A
- ZVRA 244.60
- 52 Week Low
- DHY $1.77
- ZVRA $6.19
- 52 Week High
- DHY $2.08
- ZVRA $13.16
- Technical
- Relative Strength Index (RSI)
- DHY 33.08
- ZVRA 42.38
- Support Level
- DHY $2.04
- ZVRA $8.51
- Resistance Level
- DHY $2.07
- ZVRA $9.69
- Average True Range (ATR)
- DHY 0.02
- ZVRA 0.60
- MACD
- DHY -0.00
- ZVRA -0.13
- Stochastic Oscillator
- DHY 12.50
- ZVRA 25.86
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.